Monitored anesthesia care with dexmedetomidine: A prospective, randomized, double-blind, multicenter trial

Keith A Candiotti, Sergio D. Bergese, Paula M. Bokesch, Marc A. Feldman, Wayne Wisemandle, Alex Y. Bekker

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Background: Dexmedetomidine (DEX) is increasingly being used as a sedative for monitored anesthesia care (MAC) because of its analgesic properties, "cooperative sedation," and lack of respiratory depression. In this randomized, multicenter, double-blind, Phase III Food and Drug Administration study, we evaluated the safety and efficacy of two doses of DEX for sedation of patients undergoing a broad range of surgical or diagnostic procedures requiring MAC. Methods: Three hundred twenty-six patients were randomized 2:2:1 to DEX 0.5 μg/kg, DEX 1 μg/kg, or saline placebo initial loading dose, followed by a maintenance infusion of 0.2-1.0 μg • kg • h of DEX (or equivalent volume of saline) titrated to a targeted level of sedation (≤4 on the Observer's Assessment of Alertness/Sedation Scale [OAA/S]). Study drug was started at least 15 min before placement of regional or local anesthetic block. Midazolam was given for OAA/S >4 and fentanyl for pain. The primary end-point was the percentage of patients not requiring rescue midazolam. Results: Significantly fewer patients in the 0.5- and 1-μg/kg DEX groups required supplemental midazolam compared with placebo (59.7% [80/134], 45.7% [59/129] vs 96.8% [61/63], respectively; P < 0.001) and at lower doses to achieve an OAA/S ≤4 before and during surgery compared with the saline group (1.4 and 0.9 mg vs 4.1 mg, respectively; P < 0.001, each group compared with placebo). Both DEX groups required significantly less fentanyl (84.8 and 83.6 μg vs 144.4 μg, respectively; P < 0.001, for both DEX groups versus placebo) for all surgical subtypes. Anesthesiologists indicated significantly increased ease of achieving and maintaining targeted sedation in both DEX groups compared with placebo with midazolam (P < 0.001). Patient satisfaction was significantly higher with DEX (P ≤ 0.009, both groups versus placebo). Common adverse events with DEX were protocol-defined bradycardia and hypotension that were predominately mild to moderate in severity. The incidence of clinically significant respiratory depression (defined as a respiratory rate of <8 or an oxygen saturation of <90%) was lower in DEX-treated patients (P = 0.018, for both groups versus placebo). Conclusions: DEX is an effective baseline sedative for patients undergoing MAC for a broad range of surgical procedures providing better patient satisfaction, less opioid requirements, and less respiratory depression than placebo rescued with midazolam and fentanyl.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalAnesthesia and Analgesia
Volume110
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Dexmedetomidine
Multicenter Studies
Anesthesia
Placebos
Midazolam
Fentanyl
Respiratory Insufficiency
Hypnotics and Sedatives
Patient Satisfaction
United States Food and Drug Administration
Bradycardia
Respiratory Rate
Local Anesthetics
Hypotension
Opioid Analgesics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Monitored anesthesia care with dexmedetomidine : A prospective, randomized, double-blind, multicenter trial. / Candiotti, Keith A; Bergese, Sergio D.; Bokesch, Paula M.; Feldman, Marc A.; Wisemandle, Wayne; Bekker, Alex Y.

In: Anesthesia and Analgesia, Vol. 110, No. 1, 01.01.2010, p. 47-56.

Research output: Contribution to journalArticle

Candiotti, Keith A ; Bergese, Sergio D. ; Bokesch, Paula M. ; Feldman, Marc A. ; Wisemandle, Wayne ; Bekker, Alex Y. / Monitored anesthesia care with dexmedetomidine : A prospective, randomized, double-blind, multicenter trial. In: Anesthesia and Analgesia. 2010 ; Vol. 110, No. 1. pp. 47-56.
@article{ab69bde697fd4008ac4c0bb470405d2a,
title = "Monitored anesthesia care with dexmedetomidine: A prospective, randomized, double-blind, multicenter trial",
abstract = "Background: Dexmedetomidine (DEX) is increasingly being used as a sedative for monitored anesthesia care (MAC) because of its analgesic properties, {"}cooperative sedation,{"} and lack of respiratory depression. In this randomized, multicenter, double-blind, Phase III Food and Drug Administration study, we evaluated the safety and efficacy of two doses of DEX for sedation of patients undergoing a broad range of surgical or diagnostic procedures requiring MAC. Methods: Three hundred twenty-six patients were randomized 2:2:1 to DEX 0.5 μg/kg, DEX 1 μg/kg, or saline placebo initial loading dose, followed by a maintenance infusion of 0.2-1.0 μg • kg • h of DEX (or equivalent volume of saline) titrated to a targeted level of sedation (≤4 on the Observer's Assessment of Alertness/Sedation Scale [OAA/S]). Study drug was started at least 15 min before placement of regional or local anesthetic block. Midazolam was given for OAA/S >4 and fentanyl for pain. The primary end-point was the percentage of patients not requiring rescue midazolam. Results: Significantly fewer patients in the 0.5- and 1-μg/kg DEX groups required supplemental midazolam compared with placebo (59.7{\%} [80/134], 45.7{\%} [59/129] vs 96.8{\%} [61/63], respectively; P < 0.001) and at lower doses to achieve an OAA/S ≤4 before and during surgery compared with the saline group (1.4 and 0.9 mg vs 4.1 mg, respectively; P < 0.001, each group compared with placebo). Both DEX groups required significantly less fentanyl (84.8 and 83.6 μg vs 144.4 μg, respectively; P < 0.001, for both DEX groups versus placebo) for all surgical subtypes. Anesthesiologists indicated significantly increased ease of achieving and maintaining targeted sedation in both DEX groups compared with placebo with midazolam (P < 0.001). Patient satisfaction was significantly higher with DEX (P ≤ 0.009, both groups versus placebo). Common adverse events with DEX were protocol-defined bradycardia and hypotension that were predominately mild to moderate in severity. The incidence of clinically significant respiratory depression (defined as a respiratory rate of <8 or an oxygen saturation of <90{\%}) was lower in DEX-treated patients (P = 0.018, for both groups versus placebo). Conclusions: DEX is an effective baseline sedative for patients undergoing MAC for a broad range of surgical procedures providing better patient satisfaction, less opioid requirements, and less respiratory depression than placebo rescued with midazolam and fentanyl.",
author = "Candiotti, {Keith A} and Bergese, {Sergio D.} and Bokesch, {Paula M.} and Feldman, {Marc A.} and Wayne Wisemandle and Bekker, {Alex Y.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1213/ane.0b013e3181ae0856",
language = "English",
volume = "110",
pages = "47--56",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Monitored anesthesia care with dexmedetomidine

T2 - A prospective, randomized, double-blind, multicenter trial

AU - Candiotti, Keith A

AU - Bergese, Sergio D.

AU - Bokesch, Paula M.

AU - Feldman, Marc A.

AU - Wisemandle, Wayne

AU - Bekker, Alex Y.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Dexmedetomidine (DEX) is increasingly being used as a sedative for monitored anesthesia care (MAC) because of its analgesic properties, "cooperative sedation," and lack of respiratory depression. In this randomized, multicenter, double-blind, Phase III Food and Drug Administration study, we evaluated the safety and efficacy of two doses of DEX for sedation of patients undergoing a broad range of surgical or diagnostic procedures requiring MAC. Methods: Three hundred twenty-six patients were randomized 2:2:1 to DEX 0.5 μg/kg, DEX 1 μg/kg, or saline placebo initial loading dose, followed by a maintenance infusion of 0.2-1.0 μg • kg • h of DEX (or equivalent volume of saline) titrated to a targeted level of sedation (≤4 on the Observer's Assessment of Alertness/Sedation Scale [OAA/S]). Study drug was started at least 15 min before placement of regional or local anesthetic block. Midazolam was given for OAA/S >4 and fentanyl for pain. The primary end-point was the percentage of patients not requiring rescue midazolam. Results: Significantly fewer patients in the 0.5- and 1-μg/kg DEX groups required supplemental midazolam compared with placebo (59.7% [80/134], 45.7% [59/129] vs 96.8% [61/63], respectively; P < 0.001) and at lower doses to achieve an OAA/S ≤4 before and during surgery compared with the saline group (1.4 and 0.9 mg vs 4.1 mg, respectively; P < 0.001, each group compared with placebo). Both DEX groups required significantly less fentanyl (84.8 and 83.6 μg vs 144.4 μg, respectively; P < 0.001, for both DEX groups versus placebo) for all surgical subtypes. Anesthesiologists indicated significantly increased ease of achieving and maintaining targeted sedation in both DEX groups compared with placebo with midazolam (P < 0.001). Patient satisfaction was significantly higher with DEX (P ≤ 0.009, both groups versus placebo). Common adverse events with DEX were protocol-defined bradycardia and hypotension that were predominately mild to moderate in severity. The incidence of clinically significant respiratory depression (defined as a respiratory rate of <8 or an oxygen saturation of <90%) was lower in DEX-treated patients (P = 0.018, for both groups versus placebo). Conclusions: DEX is an effective baseline sedative for patients undergoing MAC for a broad range of surgical procedures providing better patient satisfaction, less opioid requirements, and less respiratory depression than placebo rescued with midazolam and fentanyl.

AB - Background: Dexmedetomidine (DEX) is increasingly being used as a sedative for monitored anesthesia care (MAC) because of its analgesic properties, "cooperative sedation," and lack of respiratory depression. In this randomized, multicenter, double-blind, Phase III Food and Drug Administration study, we evaluated the safety and efficacy of two doses of DEX for sedation of patients undergoing a broad range of surgical or diagnostic procedures requiring MAC. Methods: Three hundred twenty-six patients were randomized 2:2:1 to DEX 0.5 μg/kg, DEX 1 μg/kg, or saline placebo initial loading dose, followed by a maintenance infusion of 0.2-1.0 μg • kg • h of DEX (or equivalent volume of saline) titrated to a targeted level of sedation (≤4 on the Observer's Assessment of Alertness/Sedation Scale [OAA/S]). Study drug was started at least 15 min before placement of regional or local anesthetic block. Midazolam was given for OAA/S >4 and fentanyl for pain. The primary end-point was the percentage of patients not requiring rescue midazolam. Results: Significantly fewer patients in the 0.5- and 1-μg/kg DEX groups required supplemental midazolam compared with placebo (59.7% [80/134], 45.7% [59/129] vs 96.8% [61/63], respectively; P < 0.001) and at lower doses to achieve an OAA/S ≤4 before and during surgery compared with the saline group (1.4 and 0.9 mg vs 4.1 mg, respectively; P < 0.001, each group compared with placebo). Both DEX groups required significantly less fentanyl (84.8 and 83.6 μg vs 144.4 μg, respectively; P < 0.001, for both DEX groups versus placebo) for all surgical subtypes. Anesthesiologists indicated significantly increased ease of achieving and maintaining targeted sedation in both DEX groups compared with placebo with midazolam (P < 0.001). Patient satisfaction was significantly higher with DEX (P ≤ 0.009, both groups versus placebo). Common adverse events with DEX were protocol-defined bradycardia and hypotension that were predominately mild to moderate in severity. The incidence of clinically significant respiratory depression (defined as a respiratory rate of <8 or an oxygen saturation of <90%) was lower in DEX-treated patients (P = 0.018, for both groups versus placebo). Conclusions: DEX is an effective baseline sedative for patients undergoing MAC for a broad range of surgical procedures providing better patient satisfaction, less opioid requirements, and less respiratory depression than placebo rescued with midazolam and fentanyl.

UR - http://www.scopus.com/inward/record.url?scp=74049113764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049113764&partnerID=8YFLogxK

U2 - 10.1213/ane.0b013e3181ae0856

DO - 10.1213/ane.0b013e3181ae0856

M3 - Article

C2 - 19713256

AN - SCOPUS:74049113764

VL - 110

SP - 47

EP - 56

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -